An Evaluation of Two Dose Routes of HDV-Interferon Administered With Ribavarin in the Treatment of Chronic Hepatitis C Nonresponders and Naive Hepatitis C Patients
A Phase II, Open Label, Multi-Center, Proof-Of-Concept Study determing whether treatment with HDV-Interferon (HDV-IFN), by oral or subcutaneous (injection) routes, and ribavirin results in similar efficacy [Rapid Virologic Response (RVR)] and safety as the reported efficacy and safety with pegylated alpha-interferon-2a and ribavirin (historical control) in patients with chronic hepatitis C (treatment naïve by oral route and non-responders by SC route respectively).
100 Clinical Results associated with Hepasome Pharmaceuticals, Inc.
0 Patents (Medical) associated with Hepasome Pharmaceuticals, Inc.
100 Deals associated with Hepasome Pharmaceuticals, Inc.
100 Translational Medicine associated with Hepasome Pharmaceuticals, Inc.